SCHEMBL7359022

SCHEMBL7359022

Oc1nccn1CC=Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 1/20 0.45
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ PAM P19021 1/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ PPARG P37231 1/20 0.38
▸ PPARA Q07869 1/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ CDK8 P49336 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10988258 0.81 OPRD1 (0.42) OPRD1NPC1RAB9ATDP1L3MBTL1
SCHEMBL10988265 0.81 OPRD1 (0.42) OPRD1NPC1RAB9ATDP1L3MBTL1
SCHEMBL7453368 0.76 GPR52 (0.44) NPC1RAB9ALMNAKMT2AESR1
SCHEMBL11148240 0.70 OPRD1 (0.42) OPRD1NPC1RAB9AL3MBTL1LMNA
SCHEMBL31696327 0.68 HDAC3 (0.46) OPRD1NPC1RAB9ATDP1L3MBTL1
SCHEMBL28003655 0.68 ALDH1A1 (0.46) OPRD1LMNAALDH1A1PAMKMT2A
SCHEMBL28003654 0.68 ALDH1A1 (0.46) OPRD1LMNAALDH1A1PAMKMT2A
SCHEMBL8347430 0.67 TBXAS1 (0.68) LMNAKMT2ATBXAS1MEN1
SCHEMBL8347428 0.67 TBXAS1 (0.68) LMNAKMT2ATBXAS1MEN1
SCHEMBL6209007 0.66 KDM4E (0.48) NPC1RAB9ATDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403805-B1 SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED JANSSEN PHARMACEUTICA N.V. (BE) 2002-06-11 — — US disclosed
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES FREYNE EDDY JEAN EDGARD (BE) 2002-06-06 — — US disclosed
EP-0819122-B1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY JANSSEN PHARMACEUTICA NV (BE) 2002-03-06 — — EP disclosed
US-5994376-A PHOSPHODIESTERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 1999-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068830-A1 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HRH2, CBR1, HRH1 OPRD1 982/4885NPC1 2611/4885RAB9A 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback